Importantly, targeting Notch signaling with gamma- secretase inhibitors suppressed the growth and chemoresistance of CD133+, CD44+, or ALDH+ cells (35), suggesting a functional requirement for Notch activity in NSCLC CSCs. This evidence concerns the gene CD44 and non-small cell lung carcinoma.